ENCell’s EN001 Enters Phase 2a Trials for CMT1A
ENCell's EN001 Enters Phase 2a Trials for CMT1A A South Korean biotech company called ENCell just...
Learn more on this topic
Related Blog Posts
The 2026 CMT Summit: What We Built Together
The 2026 CMT Summit: What We Built Together Two days. One community that keeps growing. The...
HNF Driving Progress at the 2026 MDA Clinical & Scientific Conference
HNF Driving Progress at the 2026 MDA Clinical & Scientific Conference The Hereditary...
Brews & Bingo For CMT
Join us on Thursday, Nov. 13th at 6pm, Rec Room by Conshohocken Brewing, 230 Bridge St, Phoenixville, PA 19460
CMT Summit Patient Voices
At the 2025 CMT Summit and Retreat in Nashville, the Hereditary Neuropathy Foundation (HNF) placed...
MDA Awards Grant to HNF for Groundbreaking Digital Wearable Study on CMT!
Exciting news for the Charcot-Marie-Tooth (CMT) community! The Hereditary Neuropathy Foundation...
Join Our CMT Summit Q&A Zoom
Have questions about HNF’s upcoming CMT Summit + Patient Retreat? We’re here to help! Join Us January 29th from 12:00pm – 1:30pm ET.
Alesta Therapeutics Advances ALE2 to Target Rare Forms of CMT
Early preclinical research indicates that ALE2 could effectively slow or halt the progression of these debilitating symptoms, offering new hope for patients with these rare forms of CMT.
2025 HNF CMT Summit & Wellness Retreat
Experience the 2025 HNF CMT Summit & Wellness Retreat in Nashville, TN, April 24-26!
Update on NMD Pharma Clinical Trial
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-MarieTooth Disease Type 1...
0 Comments